Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 28255272)

  • 1. Reverse the Resistance to PARP Inhibitors.
    Kim Y; Kim A; Sharip A; Sharip A; Jiang J; Yang Q; Xie Y
    Int J Biol Sci; 2017; 13(2):198-208. PubMed ID: 28255272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    Rabenau K; Hofstatter E
    Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
    Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
    BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
    Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
    Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARPi focus the spotlight on replication fork protection in cancer.
    Schlacher K
    Nat Cell Biol; 2017 Oct; 19(11):1309-1310. PubMed ID: 29087384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.
    Sunada S; Nakanishi A; Miki Y
    Cancer Sci; 2018 Apr; 109(4):893-899. PubMed ID: 29427345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.
    Vaclová T; Woods NT; Megías D; Gomez-Lopez S; Setién F; García Bueno JM; Macías JA; Barroso A; Urioste M; Esteller M; Monteiro ANA; Benítez J; Osorio A
    Hum Mol Genet; 2016 Dec; 25(24):5287-5299. PubMed ID: 27742776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in cancer therapy using PARP inhibitors.
    Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN
    Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.
    Lim D; Ngeow J
    Endocr Relat Cancer; 2016 Jun; 23(6):R267-85. PubMed ID: 27226207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
    Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
    Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posttranscriptional Regulation of
    Chand SN; Zarei M; Schiewer MJ; Kamath AR; Romeo C; Lal S; Cozzitorto JA; Nevler A; Scolaro L; Londin E; Jiang W; Meisner-Kober N; Pishvaian MJ; Knudsen KE; Yeo CJ; Pascal JM; Winter JM; Brody JR
    Cancer Res; 2017 Sep; 77(18):5011-5025. PubMed ID: 28687616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cancer therapy by PARP inhibitors].
    Seimiya H
    Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
    Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
    [No Abstract]   [Full Text] [Related]  

  • 16. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
    Duma N; Gast KC; Choong GM; Leon-Ferre RA; O'Sullivan CC
    Curr Oncol Rep; 2018 Jun; 20(8):63. PubMed ID: 29884921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
    Shah AP; Patel CN; Sureja DK; Sanghavi KP
    Folia Med (Plovdiv); 2018 Mar; 60(1):39-47. PubMed ID: 29668451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
    Noordermeer SM; van Attikum H
    Trends Cell Biol; 2019 Oct; 29(10):820-834. PubMed ID: 31421928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
    del Rivero J; Kohn EC
    Oncology (Williston Park); 2017 Apr; 31(4):265-73. PubMed ID: 28412778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of PARP inhibitors in cancer biology and therapy.
    Davar D; Beumer JH; Hamieh L; Tawbi H
    Curr Med Chem; 2012; 19(23):3907-21. PubMed ID: 22788767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.